Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A randomized, double-blind, phase IIa dose-finding study of Vandetanib (ZD6474) in Japanese patients with non-small cell lung cancer.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer - 1 Apr 2008

Kiura Katsuyuki, Nakagawa Kazuhiko, Shinkai Tetsu, Eguchi Kenji, Ohe Yuichiro, Yamamoto Nobuyuki, Tsuboi Masahiro, Yokota Soichiro, Seto Takashi, Jiang Haiyi, Nishio Kazuto, Saijo Nagahiro, Fukuoka Masahiro

Abstract excerpt

INTRODUCTION: Vandetanib (ZACTIMA) is a once-daily, oral anticancer drug that selectively inhibits vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) signaling. Vandetanib was evaluated as a monotherapy in a randomized, double-blind, dose-finding study in Japan. PATIENTS AND METHODS: Eligible patients with locally advanced or metastatic (stage IIIB/IV) or recurrent...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma
Share to Administration, Oral

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Squamous Cell

Share to Double-Blind Method

Share to Maximum Tolerated Dose

Share to Neoplasm Recurrence, Local

Share to Piperidines

Share to Quinazolines

Source

Identifiers

PMID: 18379357
DOI: 10.1097/JTO.0b013e318168d228

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A randomized, double-blind, phase IIa dose-finding study of Vandetanib (ZD6474) in Japanese patients with non-small cell lung cancer.PMID 18379357Read ↗

Vandetanib in pretreated patients with advanced non-small cell lung cancer-harboring RET rearrangement: a phase II clinical trial.Semantic proximity Read ↗

Phase I Trial of a Third Generation EGFR Mutant-Selective Inhibitor (D-0316) in Patients with Advanced Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Ensartinib (X-396) in ALK-Positive Non-Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study.Semantic proximity Read ↗

Safety, tolerability, and pharmacokinetic profile of dabrafenib in Japanese patients with BRAF V600 mutation-positive solid tumors: a phase 1 study.Semantic proximity Read ↗

Vandetanib inhibits both VEGFR-2 and EGFR signalling at clinically relevant drug levels in preclinical models of human cancer.Semantic proximity Read ↗

Clinical and biomarker outcomes of the phase II vandetanib study from the BATTLE trial.Semantic proximity Read ↗

Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer.Semantic proximity Read ↗

A Phase I Study of the Safety and Pharmacokinetics of Higher-Dose Icotinib in Patients With Advanced Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Pharmacokinetic profiles of significant adverse events with crizotinib in Japanese patients with ABCB1 polymorphism.Semantic proximity Read ↗

Effects of vandetanib on lung adenocarcinoma cells harboring epidermal growth factor receptor T790M mutation in vivo.Semantic proximity Read ↗

Usefulness of Rapid Desensitization Therapy for Severe Rash Caused by Molecularly Targeted Drugs Used in the Treatment of Non-small-cell Lung Cancer.Semantic proximity Read ↗

CYP2C19 genotype-based phase I studies of a c-Met inhibitor tivantinib in combination with erlotinib, in advanced/metastatic non-small cell lung cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.